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T-cell cross-reactivity is essential for effective immune sur-
veillance but has also been implicated as a pathway to autoim-
munity. Previous studies have demonstrated that T-cell recep-
tors (TCRs) that focus on aminimalmotif within the peptide are
able to facilitate a high level of T-cell cross-reactivity. However,
the structural database shows that most TCRs exhibit less
focused antigen binding involving contact with more peptide
residues. To further explore the structural features that allow
the clonally expressed TCR to functionally engage with mul-
tiple peptide-major histocompatibility complexes (pMHCs),
we examined the ILA1 CD8 T-cell clone that responds to a
peptide sequence derived from human telomerase reverse
transcriptase. The ILA1 TCR contacted its pMHC with a
broad peptide binding footprint encompassing spatially dis-
tant peptide residues. Despite the lack of focused TCR-pep-
tide binding, the ILA1 T-cell clone was still cross-reactive.
Overall, the TCR-peptide contacts apparent in the structure
correlated well with the level of degeneracy at different pep-
tide positions. Thus, the ILA1 TCR was less tolerant of
changes at peptide residues that were at, or adjacent to, key
contact sites. This study provides new insights into the
molecular mechanisms that control T-cell cross-reactivity
with important implications for pathogen surveillance, auto-
immunity, and transplant rejection.
Recognition of peptide-major histocompatibility complexes
(pMHCs)5 by the clonally expressed  T-cell receptor (TCR)
mediates T-cell immunity. Although TCRs generally interact
with pMHC via a conserved binding mode, with the TCR
chain positioned over theMHC1 domain and the TCR chain
positioned over the MHC2 domain, the TCR complementar-
ity-determining region (CDR) loops can use a variety of mech-
anisms to probe both the MHC surface and bound peptide (1).
This flexible binding probably mediates the ability of a single
TCR to interact productively with a large range of different
epitopes (2–6). Thus, TCR degeneracy enables the approxi-
mately 25 million distinct TCR clonotypes expressed by an
individual host (7) to have the potential to recognize the entire
theoretical peptide universe that could be presented by MHC
(2, 8),minimizing the likelihood of pathogens escaping immune
surveillance. Given the highly diverse number of TCR-pMHC
binding modes seen to date, it is reasonable to predict that
different TCRs will exhibit distinct levels of cross-reactivity,
depending on the chemical characteristics of their CDR loops
and how they interact with pMHC. Such distinctions could
determine whether certain TCRs are more likely to offer suffi-
cient protection against hypervariable pathogens, such as
human immunodeficiency virus type 1, hepatitis B virus, hepa-
titis C virus, and influenza, or conversely to trigger autoim-
mune disease.
Although new quantitative information on the extent of
T-cell cross-reactivity has recently come to light (3, 5, 9), the
molecular rules that determine this important facet of cellular
adaptive immunity remain unclear. Understanding TCR bind-
ing degeneracy, and the ensuing T-cell cross-reactivity it
enables, is of emerging importance given the increasing use of
T-cell therapies usingmodified TCRs, one of which has already
demonstrated the dangers of unintentional T-cell cross-reac-
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tivity with self-ligands (10–12). Currently, there are few exam-
ples of TCR-pMHC complex structures for which the cross-
reactivity profiles of the corresponding T-cell clone have also
been determined (3, 13, 14). In a previous study, we demon-
strated that an insulin-reactive humanCD8T-cell clone (1E6)
could recognize upward of one million unique peptide ligands.
The structure of the 1E6 TCR with its cognate ligand revealed
focused TCR-peptide binding with the interaction of only two
TCR residues and two adjacent peptide residues accounting for
the majority of the binding interface. We speculated that this
focused binding might enable the 1E6 TCR to tolerate changes
outside of the core motif, mediating the high level of degener-
acy. In support of this, another study recently demonstrated
that a high level of cross-reactivity was mediated by similar
focused TCR-peptide binding by an MHC class II-restricted
TCR (13). However, whether TCRs must exhibit focused
peptide binding to cross-react remains unclear. This is an
important question because, unlike the two examples of
focused TCR-peptide binding mentioned above, most TCRs
that have been studied structurally to date makemore compre-
hensive interactions with the pMHC surface. Thus, whether a
“typical” TCR binding footprint can underpin T-cell cross-re-
activity remains unknown.
Here, we used a well characterized CD8T-cell clone (ILA1)
(15) that responds to residues 540–548 (sequence, ILAKFL-
HWL) of human telomerase reverse transcriptase to further
investigate the structural basis of TCR degeneracy. We have
previously characterized a limited number of altered peptide
ligands (APLs) for the ILA1 T-cell clone that exhibit different
potencies in terms of T-cell activation (9, 15), corresponding
to a wide range of binding affinities with the ILA1 TCR (15–
17). These previous findings clearly demonstrate that the
ILA1 T-cell clone can recognize multiple different peptide
ligands. Here, we solved the structure of the ILA1 TCR in
complex with HLA-A*0201-ILAKFLHWL (A2-ILA) and sev-
eral previously defined APLs. Combined with biophysical
analysis, we demonstrate the molecular mechanism for anti-
gen discrimination by the ILA1 TCR and model the mode of
cross-reactivity with these APLs. In addition, we used our
previously published peptide sampling approach (3) to esti-
mate the number of pMHCI molecules that could be recog-
nized by the ILA1 TCR. These data offer novel insight into
the molecular factors that determine T-cell cross-reactivity,
extending our understanding of the nature of T-cell antigen
discrimination.
Results
The ILA1 TCR Makes a Broad Contact Network with
A2-ILA—We solved the structure of the ILA1 TCR-A2-ILA
complex at 2.8 Å in space group P 1 21 1 with crystallographic
Rwork/Rfree ratios within accepted limits as shown by the theo-
retically expected distribution (18) (Table 1). The electron den-
sity was high quality throughout, represented by an omit map
analysis of the ILA peptide (Fig. 1A). The ILA1 TCR utilized a
canonical bindingmode to engage A2-ILA (Fig. 1A) with a bur-
ied surface area (2507.2 Å2) and surface complementarity
TABLE 1
Data collection and structure refinement statistics
Values in parentheses refer to the highest resolution bin. One crystal was used for solving each structure. DLS, Diamond Light Source; r.m.s., root mean square; n/a, not
applicable; CC1/2, correlation coefficient.
ILA1-A2-ILA A2-ILA3G8R A2-ILA3G A2-ILA8T A2-ILA8E
Data collection
Protein Data Bank code 5MEN 5MEO 5MEP 5MEQ 5MER
Space group P 1 21 1 P 21 21 21 P 21 21 21 P 1 21 1 P 21 21 21
Beamline DLS I24 DLS I04 DLS I02 DLS I04 DLS I02
Cell dimensions
a (Å) 93.2 49.2 119.4 53.34 45.7
b (Å) 48.7 74.9 169.6 81.44 119.0
c (Å) 118.1 125.8 47.1 56.77 170.3
 (°) 90 90 90 90 90
 (°) 108.2 90 90 113.5 90
 (°) 90 90 90 90 90
Resolution maximum (Å) 2.81 (2.88–2.81) 1.77 (1.82–1.77) 2.71 (2.78–2.71) 2.27 (2.33–2.27) 1.88 (1.93–1.88)
Rmerge (%) 0.100 (0.73) 0.105 (0.718) 0.105 (.831) 0.086 (0.632) 0.098 (0.621)
Total measurements 91,454 (6,913) 332,927 (22,417) 195,005 (13,976) 74,664 (5,741) 545,975 (42,439)
Unique reflections 25,031 (1,865) 46,011 (3,362) 26,894 (1,974) 20,523 (1,527) 76,630 5,603
I/I 9.2 (1.9) 10.5 (2.5) 14.1 (2.3) 12.8 (1.9) 10.8 (3.2)
CC1/2 n/a n/a 0.997 (0.714) 0.997 (0.842) 0.997 (0.913)
Completeness (%) 99.7 (99.8) 100 (100) 100 (100) 99.3 (98.9) 99.9 (100)
Multiplicity 3.7 (3.7) 7.2 (6.7) 7.3 (7.1) 3.5 (3.8) 7.1 (7.6)
Refinement
Resolution (Å) 56.11–2.81 48.16–1.77 42.39–2.71 48.90–2.27 34.06–1.9
No. reflections in work set 23,666 43,626 25,511 19,484 72,747
No. reflections in Rfree set 1,267 2,319 1,333 1,023 3,797
Rwork/Rfree (%) 18.9/27.2 17.1/21.4 18.2/23.9 20.3/26.4 18.4/22.4
Mean B value (Å2) 57.1 27.7 52.2 37.7 33.0
Wilson B-factor (Å2) 70.5 21.9 39.6 32.97 28.6
Overall coordinate error (Å) 0.377 0.082 0.252 0.232 0.098
r.m.s. deviations
Bond lengths (Å) 0.017 0.019 0.013 0.019 0.019
Bond Angles (°) 2.025 1.983 1.658 1.976 1.967
Ramachandran plot statistics
Most favored region (%) 92.27 97.85 97.23 96.54 98.12
Allowed region (%) 6.38 2.15 2.77 3.19 1.88
Outliers (%) 1.35 0 0 0.27 0
Structural Basis of T-cell Cross-reactivity
JANUARY 20, 2017•VOLUME 292•NUMBER 3 JOURNAL OF BIOLOGICAL CHEMISTRY 803
 at U
niversity of Bristol Library Services on February 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(TCR-pMHC  0.641) within the normal range (Table 2) (1).
The TCR -chain was orientated over the MHCI 1 helices,
and the TCR -chain was oriented over the MHCI 2 helices
(Fig. 1B), positioning the CDR loops of the ILA1 TCR over the
central portion of the peptide, enabling contacts with 4 of the 9
peptide residues (Fig. 1C). Peptide residues Lys-4 and Trp-8
engaged in a complex network of contacts with the TCR
CDR1/3 loops and CDR1/3 loops, respectively, contribut-
ing 39 of the 49 total peptide contacts (Table 2). Binding to
Lys-4 involved a tight ball-and-socket interaction with 7
TCR residues, whereas contacts with Trp-8 were less restric-
tive, involving only TCR -chain residues Glu-30 and Gln-96
(Table 3 and Fig. 1C). The 49 TCR interactions with peptide
were supported by 58 contacts with MHC, involving 12 TCR
-chain residues and 4 TCR -chain residues (Fig. 1D), con-
tributing to the slightly TCR -chain-skewed binding mode
(, 58%; , 42% of total contacts). Notably, the TCR -chain
residue Arg-68 in the framework region loop (outside of the
FIGURE 1. The ILA1 TCR uses a broad binding footprint to engage A2-ILA. A, the overall binding mode of ILA1 TCR (blue and cyan schematic; CDR loops
shown inmulticolored schematic) in complexwith A2-ILA (gray schematic and orange sticks). The box shows the observedmap (top) at 1.0 and an omitmaps
(below) in which themodel was refined in the absence of the ILA peptidewith difference density contoured at 3.0; positive contours are shown in green, and
negative contours are shown in red. B, position of the ILA1 TCR CDR loops (multicolored sticks) with the ILA peptide (orange sticks) is shown in the HLA-A*0201
binding groove (gray surface). The crossing angle of the ILA1 TCR (black line) was calculated using previously published parameters (37). Briefly, this crossing
angle represents the angle between a best fit straight line through the C atoms from the twoMHC helices and a line that links the disulfide bond in the TCR
-chain variable region to the disulfide bond in the TCR-chain variable region. C, interaction between residues in the ILA1 TCR CDR loops (multicolored sticks)
and the ILA1 peptide (orange sticks) with theMHC 1 helix shown as a gray schematic.D, the ILA1 TCR residues in the CDR loops that contact theMHC surface
are shown inmulticolored schematic, and the surface with the MHC binding groove is shown in gray schematic and surface. CDR loops are colored as follows
throughout: CDR1, red; CDR2, green; CDR3, blue; CDR1, yellow; CDR2, purple; and CDR3, cyan.
TABLE 2
ILA1-A2-ILA contact summary
Buried surface area, 2507.2 Å2; surface complementarity for TCR-MHC, 0.635;
surface complementarity for TCR-peptide, 0.707; surface complementarity for
TCR-pMHC, 0.641; crossing angle, 51.8°, calculated as described previously (37).
vdW, van der Waals; FW, framework region.
vdW
(<4 Å)
H-bonds
(<3.4 Å)
Salt bridges
(<3.4 Å)
MHC 58 6 2
Peptide 49 4 1
Peptide Lys-4 20 2 1
Peptide Trp-8 19 2 0
TCR 62 7 3
CDR1 16 2 0
CDR2/FW 9 2 2
CDR3 37 3 1
TCR Asp-97 6 2 0
TCR Arg-68 4 0 2
TCR 45 3 0
CDR1 13 0 0
CDR2 7 0 0
CDR3 25 3 0
TCR Gln-96 18 3 0
Total contacts 107 10 3
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traditionalCDR loops) formed two salt bridgeswithMHCresidue
Glu-166, and all of theMHCrestriction triad residues (Arg-65,Ala-
69, andGln-155) (19) interactedwith the ILA1TCR (Table 3).
We have shown previously that the ILA1 TCR binds with a
moderate/weak affinity (KD  34 M) to A2-ILA (20), consis-
tent with the observation that TCRs specific for self-pMHCIs
FIGURE 2. Thermodynamic analysis of the ILA1 TCR with A2-ILA. A, eight to ten serial dilutions of the ILA1 TCR were injected in duplicate over A2-ILA at 5,
13, 21, 25, 29, and 37 °C. The equilibrium binding constants (KD) were calculated using a non-linear curve fit (y  (P1x)/P2  x)), and kinetic and affinity
parameters are shown in the table.B, thebinding free energies,G0 (G0RT lnKD), wereplotted against temperature (K) usingnon-linear regression to fit the
three-parameter van ’t Hoff equation (RT ln KDH
0 TS0Cp0(T T0) TCp
0 ln(T/T0) with T0 298 K).
TABLE 3
ILA1-A2-ILA contacts
A 3.4 Å cutoff was used for H-bonds and salt bridges, and a 4 Å cutoff was used for van der Waals (vdW). FW, framework region.
CDR loop Gene usage TCR residue Peptide residue MHC residue vdW (<4 Å) H-bonds (<3.4 Å)
CDR1 TRAV22 Asp-27O2 Thr-163O1 4 1
TRAV22 Asp-27O1 Glu-166O2 2 1
TRAV22 Ser-28 Ala-158 1
TRAV22 Val-29 Gln-155 4
TRAV22 Val-29 Lys-4 4
TRAV22 Asn-30 Gln-155 1
CDR2 TRAV22 Tyr-48 Glu-154 1
TRAV22 Tyr-48 Gln-155 2
TRAV22 Ser-51O Glu-154O 1 1
TRAV22 Ser-51 Arg-157 1
TRAV22 Gln-55O1 Glu-154O2 1
FW TRAV22 Arg-68NH1/NH2 Glu-166O1/O2 4 2 salt bridges
CDR3 TRAJ40 Asp-91O1 Lys-4N	 3 1 salt bridge
TRAJ40 Ser-92O Lys-4N	 2 1
TRAJ40 Ala-93 Lys-66 1
TRAJ40 Ala-93 Thr-163 2
TRAJ40 Ala-93 Lys-4 2
TRAJ40 Thr-94O Lys-66N	 3 1
TRAJ40 Thr-94 Trp-167 3
TRAJ40 Ser-95 Lys-4 4
TRAJ40 Gly-96 Arg-65 3
TRAJ40 Thr-97O Lys-4N	 3 1
TRAJ40 Tyr-98 Lys-66 3
TRAJ40 Tyr-98 Ala-69 2
TRAJ40 Tyr-98 Lys-4 2
TRAJ40 Tyr-98 Leu-6 4
CDR1 TRBV6 Glu-30 Trp-8 13
CDR2 TRBV6 Val-50 Val-152 1
TRBV6 Val-50 Leu-6 1
TRBV6 Val-50 Trp-8 1
TRBV6 Ile-54 Gln-72 4
CDR3 TRBJ1-1 Tyr-95 Lys-146 5
TRBJ1-1 Tyr-95 Ala-150 2
TRBJ1-1 Gln-96 Lys-146 2
TRBJ1-1 Gln-96O1 Trp-147N1 4 1
TRBJ1-1 Gln-96 Ala-150 1
TRBJ1-1 Gln-96 Val-152 1
TRBJ1-1 Gln-96 Leu-6 2
TRBJ1-1 Gln-96 His-7 3
TRBJ1-1 Gln-96O1 Trp-8N/O 5 2
Structural Basis of T-cell Cross-reactivity
JANUARY 20, 2017•VOLUME 292•NUMBER 3 JOURNAL OF BIOLOGICAL CHEMISTRY 805
 at U
niversity of Bristol Library Services on February 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
usually bind at the lower end of the TCR-pMHC affinity scale
(21, 22). We performed a thermodynamic analysis of the ILA1
TCR-A2-ILA interaction by measuring binding using surface
plasmon resonance at a range of temperatures (5–37 °C) (Fig. 2A).
These analyses demonstrated that the weak affinity was not
temperature-dependent, ranging from KD 34 (25 °C) to 74 M
(5 °C). At physiological temperature (37 °C), the affinity was in the
middle of this range (KD 48M).The energetic analysis (Fig. 2B)
revealed that the ILA1 TCR-A2-ILA interaction was driven
entropically (TS  5.86 kcal/mol) with only a minor change in
enthalpy (H0.16 kcal/mol). These values indicate almost no
net loss, or gain, in electrostatic interactions during complex for-
mation, indicative of structural reordering of the TCR and/or
pMHC when binding. The entropic contribution suggested that
ordered water molecules are squeezed out at the interface as the
TCR and pMHC engage. Overall, these analyses demonstrated
that the ILA1 TCR utilizes a relatively broad binding footprint,
contactingspatiallydistant regionsonthepeptideand involving21
different TCR residues contacting 17 A2-ILA residues (4 peptide
and 13 MHC residues), contributing to an entropically driven,
moderate-to-weak affinity interaction.
APLs Guide ILA1 Antigen Recognition through Structural
Alterations in Peptide Conformation—We have previously
characterized a number of APLs that alter the T-cell activation
profile and TCR binding affinity of the ILA1 T-cell clone (9, 15,
FIGURE 3. Density plot, omit map, and B-factor analysis of ILA1 peptide variants. A–D, top, the observed map at 1.0  is shown. Bottom, omit maps are
shown in which the model was refined in the absence of the ILA peptide variants with difference density contoured at 3.0 ; positive contours are shown in
green, and negative contours are shown in red. A, A2-ILGKFLHRL (purple sticks). B, A2-ILGKFLHWL (green sticks). C, A2-ILAKFLHTL (sand sticks).D, A2-ILAKFLHEL
(black sticks). A2-ILAKFLHRL was solved previously (23). E–J, each APL is colored by B-factor with light blue representing a low B-factor and red representing a
high B-factor. The conformation of each APL (sticks) with arrows indicating the direction of each residue in the peptide (solvent-exposed, MHC anchor, or in
between) with the MHC 1 helix shown as a gray schematic. Residues in red indicate differences from the index sequence. An up arrow indicates solvent-
exposed, a down arrow indicates anchor position, and no arrow indicates an intermediate position. E, A2-ILAKFLHWL. F, A2-ILGKFLHRL. G, A2-ILGKFLHWL. H,
A2-ILAKFLHRL. I, A2-ILAKFLHTL. J, A2-ILAKFLHEL.
FIGURE 4. Stability of HLA-A2-ILA variants using circular dichroism. A, CD
thermal denaturation curves recorded at 218 nmare shown for selected pep-
tide-HLA class I samples. Dots represent measured values fitted assuming a
two-state trimer-to-monomer transition (dashed lines) as described under
“Experimental Procedures.” B, bar graphs of the thermal stability with respect
to melting temperature (upper panel) and van ’t Hoff’s enthalpy of unfolding
(lower panel). Error bars represent S.D. resulting from the multivariable curve
fitting.
Structural Basis of T-cell Cross-reactivity
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16). To investigate how these ligands adjust TCR interactions
to tune affinity, we solved the structure of four APLs
(A2-ILA3G8R, ILGKFLHRL; A2-ILA3G, ILGKFLHWL; A2-
ILA8T,ILAKFLHTL; and A2-ILA8E, ILAKFLHEL), included
our previously published APL structure (A2-ILA8R, ILAKFL-
HRL) (23), and used the ILA1-A2-ILA complex as amodel. The
electron densitywas high quality throughout, represented by an
omitmap analysis of the ILA peptide variants (Fig. 3,A–D), and
B-factor analysis indicated that there were nomajor differences
in peptide mobility across the peptide variants (Fig. 3, E–J).
Thermal stability analysis demonstrated that most of the APLs
had a similar apparentTm value (the term “apparentTm” is used
here because the protein irreversibly aggregates at high temper-
ature) of around 55 °C with extremes in the range of 50 to 61 °C
(Fig. 4). These similar stabilities are consistent with our previ-
ous observation that all these APLs bind equally to HLA-A2 on
the cell surface (15). As we have shown previously in other
systems (24), apparentTm values correlated poorlywith antigen
potency (for instance, A2-ILA3G had the lowest apparent Tm
value but was a potent activator of the ILA1 T-cell clone), sug-
gesting that different pMHC cell surface expression levels were
a minor factor in T-cell recognition. The A2-ILA3G structure
was determined at 2.7 Å resolution, and the other APL struc-
tures were determined at resolutions between at 1.9 and 1.8 Å
with crystallographic Rwork/Rfree ratios within accepted limits
as shown by the theoretically expected distribution (18) (Table
1). The overall conformations of A2-ILA3G8R, A2-ILA3G, and
A2-ILA8R were virtually identical to A2-ILA (Fig. 5,A–D) with
Lys-4, Leu-6, and Trp-8 pointing up and away from the MHC
binding groove and Leu-2, Phe-5, His-7, and Leu-9 acting as
primary and secondary anchors, indicating that a molecular
mimicry mechanism underpins ILA1 TCR recognition of these
APLs. In contrast, in the A2-ILA8T and A2-ILA8E structures,
peptide residues 5–7 were flipped so that Leu-6 acted as a sec-
ondary anchor and Phe-5 and His-7 were in more solvent-ex-
posed positions (Fig. 5, E and F). In both peptide variants, the
mutated residue was at position 8, distal from this structural
rearrangement. Closer inspection of the structures did not
reveal an obvious mechanism for this indirect effect on peptide
conformation.
We next explored the binding affinity of the ILA1 TCR for
the APLs included in this study using previously published (9,
15, 16) and new data (Fig. 6, A–E, and Table 4). Despite the
relatively weak affinity between the ILA1 TCR and the natural
A2-ILA ligand (KD  34 M), the ILA1 TCR could recognize
A2-ILA3G8R andA2-ILA3Gwith antiviral-like affinities (KD
1.0 and 3.7 M, respectively). Both of these ligands included
substitution of peptide residue 3 fromAla to Gly, a substitution
that was clearly indicated in our previously published unbiased
combinatorial peptide library screening using the ILA1 T-cell
clone (9). Structural modeling of the ILA1 TCR with these
ligands indicated that interaction with the N-terminal portion
of the peptide was likely to be very similar for both ligands (Fig.
6,F andG).However, forA2-ILA3G8R, amajor reorientation of
TCR -chain residue Gln-96 would be required to tolerate Arg
at position 8 in the peptide. For both of these ligands, the extra
flexibility, afforded at the N terminus of the peptide by the
substitution of Gly compared with Ala, may enable the ILA1
TCR to establish enhanced contacts with peptide residue Lys-4.
This represents a likely mechanism for the stronger affinity,
supported further by the observation that all of the other APLs
that did not include Gly at position 3 were bound by ILA1 with
weaker affinity compared with the ILA1-A2-ILA interaction
(Fig. 6, C–E). Structural modeling of ILA1 in complex with
A2-ILA8R (Fig. 6H) revealed the same potential for steric hin-
drance between the TCR -chain residues Glu-30 and Gln-96
but without the compensatory substitution at position 3. The
structural rearrangement that would be required for ILA1 to
FIGURE 5. Structural analysis of ILA1 TCR ligands. Shown is the conformation of each APL (sticks) demonstrating the direction of each residue in the
peptide (solvent-exposed, MHC anchor, or in between) with the MHC 1 helix shown as a gray schematic. Residues in red indicate differences from the
index sequence. An up arrow indicates solvent-exposed, a down arrow indicates anchor position, and no arrow indicates an intermediate position. A,
A2-ILAKFLHWL (orange sticks). B, A2-ILGKFLHRL (purple sticks). C, A2-ILGKFLHWL (green sticks).D, A2-ILAKFLHRL (brown sticks) (reproduced from Ref. 23).
E, A2-ILAKFLHTL (sand sticks). F, A2-ILAKFLHEL (black sticks). The circled residues in E and F face in different directions as compared with the index
telomerase sequence (ILAKFLHWL) in A.
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bind to A2-ILA8R (KD  151 M) was reflected by a much
weaker affinity compared with ILA1-A2-ILA (KD  34 M).
Both A2-ILA8T and A2-ILA8E ligands underwent a conforma-
tional transition compared with the other APLs (Fig. 5). Mod-
eling demonstrated that this alteration could lead to a steric
conflict between TCR-chain residueGln-96 and the C-termi-
nal residues of the peptide (Fig. 6, I and J). However, the posi-
tion of peptide residue Phe-5 in A2-ILA8T may allow for com-
pensatory interactions with TCR -chain residues Asp-91 and
Tyr-98, which are not present with A2-ILA8E. Furthermore,
the smaller Thr-8 side chain in A2-ILA8T, compared with
Glu-8 in A2-ILA-8E, would require smaller modifications in
TCR docking. Taken together, these structural distinctions
may explain the extremely weak affinity observed for ILA1
binding to A2-ILA8E compared with A2-ILA8T (KD values
500 M and 28 M, respectively).
Quantification of ILA1 TCR Degeneracy—Our previous
investigations have demonstrated that even single residue sub-
stitutions outside of the two main peptide interaction zones
(Lys-4 and Trp-8) could have a substantial impact on the ILA1
TCR-A2-ILA complex, reflected by the different binding affin-
ities and antigen potencies shown here and published previ-
ously (9, 15, 16). We next generated a degeneracy curve for the
ILA1 TCR using our previously described approach that quan-
tifies TCR cross-reactivity (3).
Combinatorial peptide library scan data were used to design
four different motif-restricted peptide sets (I, XLGXXXXRL
(total set size, 195); II, XLXKFLXXL (total set size, 194); III,
XLG(K/L)F(L/I)(M/F/Y/N/H)(R/T/Y/K/S/F/H/I/L/M/Q/
V/G/N)(L/V) (total set size, 10,640); and IV, (A/I/L/M/P/
Q/W)L(G/A)(K/L)F(L/I)(N/H)(F/K/N/Q/T/Y)(L/V) (total set
size, 1344) where X denotes any of the 19 proteogenic amino
acids excluding cysteine). Between 19 and 30 peptides were
sampled at random from each of these motif-restricted pep-
tides cohorts. In addition, we performed importance sam-
pling where 20 peptides were sampled from an effective sam-
ple size of 1.5  107. The pEC50 for each peptide was
estimated by simultaneous curve fitting (Fig. 7), and these
values were used to construct a degeneracy curve for the
ILA1 TCR (Fig. 8A). These analyses indicated that ILA1
could recognize 2  103 peptides with a functional sensi-
tivity at least as high as 1⁄10 the functional sensitivity of the
optimal agonist. At 2 orders of magnitude from the optimum
(i.e. peptides ranging from 1⁄100 of the optimal agonist to the
optimal agonist) 4  104 peptides could be recognized by
the ILA1 T-cell clone.
This analysis suggests that the ILA1 TCR can cross-react
with a diverse peptide universe. Although smaller than the esti-
mated number of peptides recognized by the 1E6 T-cell clone
(106), it should be noted that 1E6 recognizes a 10-mer pep-
tide, whereas ILA1 recognizes a 9-mer. Thus, the peptide uni-
verse under consideration for 1E6 is 20 times larger than that
for ILA1. Although it is unknown how this difference in peptide
length affects the comparison between the two degeneracy pro-
files, this difference may partly explain why ILA1 appears to be
less cross-reactive than 1E6. This analysis also demonstrated a
different pattern of cross-reactivity between the 1E6 and ILA1
T-cell clones that was consistent with the respective binding
footprints of their TCRs. The 1E6 T-cell clone could recog-
nize a large number of sublibraries (46 in total) outside of the
central binding zone (residues 4–6) (Fig. 8B). In contrast,
the ILA1 T-cell clone was generally more sensitive across the
peptide backbone, reflecting a more globally coordinated
interaction between the ILA1 TCR and the antigenic peptide
(Fig. 8C). Taken together, these results are broadly consis-
tent with the idea that different TCR binding footprints (i.e.
TCRs that focus on a minimal peptide motif compared with
TCRs that make contacts across the peptide backbone) can
FIGURE 6. Equilibrium binding analysis and structural modeling of the
ILA1 TCR interaction with the APLs. Binding affinity of the ILA1 TCR inter-
actionwith different APLs at 25 °C is shown. Eight to ten serial dilutions of the
ILA1 TCR were injected over A2-ILA8R and A2-ILA3G8R, and representative
data from three independent experiments are plotted after deducting bind-
ing to a control sample (HLA-A*0201-ALWGPDPAAA). The equilibrium bind-
ing constants (KD) were calculated using a non-linear curve fit (y (P1x)/P2
x)). A, ILA1-A2-ILA3G8R. B, ILA1-A2-ILA3G (reproduced from Ref. 15). C, ILA1-
A2-ILA8R. D, ILA1-A2-ILA8T (reproduced from Ref. 15). E, ILA1-A2-ILA8E
(reproduced from Ref. 15). The ILA1 TCR was modeled with each of the APL
ligands by aligning the uncomplexed APLs with A2-ILA in the ILA1-A2-ILA
complex structure (HLA-A*0101 1 helix shown in gray schematic in F–J).
Potential steric clashes arehighlighted in red circles. F, A2-ILA3G8R (peptide in
purple) showingmodeled positions of the TCR CDR3 and - loops (blue and
cyan, respectively). G, A2-ILA3G (peptide in green) superposed with the
A2-ILA peptide (orange). H, A2-ILA8R (peptide in brown) showing modeled
positions of the TCR CDR1, -2, and -3 / loops (yellow, pink, and cyan, respec-
tively). I, A2-ILA8T (peptide in sand) showing modeled positions of the TCR
CDR3 and - loops (blue and cyan, respectively). J, ILA1-A2-ILA8E (peptide in
black) showing modeled positions of the TCR CDR3 and - loops (blue and
cyan, respectively).
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enable T-cell cross-reactivity, adding further support to the
general idea that T-cells must be cross-reactive to fully pro-
tect us against a highly variable pathogen universe (for a
review, see Ref. 8).
Discussion
Tomount effective immune responses in the face of a diverse
antigenic milieu using a limited set of TCRs (estimated 25
million distinct clonotypes in an individual), each T-cell must
be able to interact productively with a vast array of different
antigens (2, 8). Indeed, recent experimental evidence supports
this notion, including our own study demonstrating that a sin-
gle T-cell clone can recognize over one million different pep-
tides at physiologically relevant concentrations (3). However,
structural investigations of TCR-pMHC interactions have
demonstrated that the TCR can establish a distinct and highly
specific interaction with both peptide and MHC. In keeping
with such specificity of binding requirements, even single
mutations at key residues in the TCR, peptide, orMHC that are
involved in the binding interface have been shown to abrogate
antigen recognition (25–29). The importance of T-cell cross-
reactivity is manifest not only in effective immune surveillance
(2, 8) but also in autoreactivity (30) and the design of therapeu-
tics (10, 11). Structural rules must therefore exist that allow
cross-reactivity to take place; here, we report early steps toward
deconstructing these rules.
We investigated a TCR isolated from ILA1, a well character-
ized HLA-A*0201-restricted, telomerase-specific, CD8
T-cell clone. Our previous work has shown that ILA1 cross-
reacts with an array of APLs with different potencies, tuned
by the CD8 co-receptor, and that antigen “potency” gener-
ally correlates directly with the affinity of TCR binding (9,
15). Here, we solved the complex structure of the ILA1 TCR
with the natural index ligand (A2-ILA) and used the struc-
tures of a number of unligated APLs to model the mode of
APL recognition and determine the structural basis for ILA1
cross-reactivity.
We have demonstrated previously that the ILA1 T-cell clone
is particularly sensitive to APLs with modifications at peptide
residues 3 and 8 (15). The unligated structures of fiveAPLswith
alterations in these positions demonstrated that the overall
conformation of the C peptide backbone could be altered by
introduction of Thr orGlu at position 8, possibly explaining the
weaker binding affinity between ILA1 and A2-ILA8R and
between ILA1 andA2-ILA8E. In contrast, substitution of Ala to
Gly at peptide residue 3 enhanced recognition, and Gly at this
position was strongly recognized in combinatorial peptide
library screens (9). Our structural analysis indicated that the
surmised extra flexibility afforded to theN terminus of the pep-
tidemediated by substitution at position 3withGlywould likely
enable more favorable interactions with Lys-4, which made a
network of contacts with the ILA1 TCR through a “ball-and-
socket”-like interaction. In fact, substitution at position 3 with
Gly could override the negative impact ofmodifications to pep-
tide residue 8, revealed by the enhanced binding affinity of the
ILA1-A2-ILA3G8R interaction (KD  1.0 M) compared with
the index peptide (KD 34M) and ILA8R (KD 151M). Our
structural analysis demonstrated that, again, even single pep-
tide substitutions outside of the main interaction interface
could have a substantial impact on TCR binding affinity and
T-cell antigen potency, consistent with our previous data (9, 15,
16). These observations add further evidence to our recent find-
ings (19, 31–34) that peptide presentation by MHCI can be
dynamic and difficult to predict.
Recent reports have demonstrated that TCRs using focused
TCR-peptide binding can be highly cross-reactive (6, 36). How-
ever, this binding footprint is not representative of most TCRs
described in the literature. Indeed, on average, TCR-peptide
binding is spread out over 60% of the peptide backbone for
MHCI-restricted epitopes, often including contacts with both
theN- and C-terminal regions of the peptide (1, 37). This inter-
connected binding network between the TCR and the peptide
may not allow a high degree of cross-reactivity because most
peptide modifications could impact binding. Unlike the
focused TCR-peptide binding utilized by the 1E6 (6) and 42F3
(38) TCRs, the ILA1 TCR utilized a more representative
binding footprint. This was reflected by a larger buried sur-
face area value (2540 Å for ILA1 compared with 1640 Å for
1E6) and a binding motif that included contacts spread out
over peptide residues 4–8. Thus, we explored the conse-
quences of the ILA1 TCR binding footprint on ILA1 T-cell
cross-reactivity using our previously publishedmethodology
(3). Despite the broader peptide contact zone utilized by the
ILA1 TCR, the ILA1 T-cell clone was still able to recognize
4  104 peptides with equal or greater sensitivity com-
pared with the index peptide and many more at lower
potency. These data suggest that although the TCR binding
TABLE 4
ILA1 TCR binding affinity to peptide variants
KD was calculated from equilibrium binding experiments. n/m, kinetics were too fast to accurately measure.
HLA-A*0201-ILA variant kon koff
2 for
kon and koff KD
M1 s1 s1 M
HLA-A*0201-ILGKFLHRL 3 104 0.16 4.2 1.0	 0.1
HLA-A*0201-ILGKFLHWL (39) 1.6 104 0.05 3.6 3.7	 0.2
HLA-A*0201-ILGKFLHTL (17) 1.95 104 0.05 2.5 2.5	 0.5
HLA-A*0201-ILAKFLHYL (39) n/m n/m n/m 22.6	 2.1
HLA-A*0201-ILAKFLHWL (20) 4.5 103 0.15 4.3 34	 2
HLA-A*0201-ILAKFLHTL (39) 2.2 103 0.08 1.9 28	 5
HLA-A*0201-ILAKFLYWL (39) n/m n/m n/m 82	 8
HLA-A*0201-ILALFLHWL (16) 1.7 103 0.2 4.2 117	 6
HLA-A*0201-ILAKFLHRL n/m n/m n/m 151	 8
HLA-A*0201-ILAKYLHWL (17) 1.3 103 0.32 3.5 242	 20
HLA-A*0201-ILAKFLHEL (39) n/m n/m n/m 500
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footprint is very likely to tune T-cell cross-reactivity to some
degree the ability of T-cells to recognize a vast array of dif-
ferent peptides is likely to be commonplace.
In summary, we demonstrate that the interaction between a
TCR from a human CD8 T-cell clone that recognizes a pep-
tide sequence from an important tumor antigen contacts the
peptide at spatially distant sites along the peptide backbone.
The affinity of this TCR can be tuned by various peptide mod-
ifications through both direct and indirect effects, demonstrat-
ing the dynamic nature of the interaction among TCR, peptide,
and MHC. Even though the ILA1 T-cell clone was sensitive to
modifications along the peptide backbone, consistent with its
broad binding interface, it was still able to cross-react with a
vast array of different peptides. These data demonstrate that
focused TCR-peptide binding is not a requirement for T-cell
degeneracy. Indeed, a broader binding footprint, as observed in
most TCR-pMHC structures reported to date, is also likely to
facilitate T-cell cross-reactivity. These results have important
implications for immune surveillance, i.e. how a limited set of
TCRs can recognize all potential antigens variants, and the
complex mechanisms that may lead to autoreactivity mediated
by molecular mimicry.
Experimental Procedures
T-cells andTarget Cells—The ILA1CD8T-cell clone is spe-
cific for the HLA-A*0201-restricted human telomerase reverse
transcriptase-derived epitope ILAKFLHWL (residues 540–
548) (39), and the 1E6 T-cell clone is specific for the human
leukocyte antigen HLA-A*0201-restricted autoantigen prepro-
insulin epitope ALWGPDPAAA (residues 15–24) (40). CD8
T-cell clones were maintained in RPMI 1640 medium (Life
Technologies) containing 100 units/ml penicillin (Life Tech-
nologies), 100 mg/ml streptomycin (Life Technologies), 2 mM
L-glutamine (Life Technologies), and 10% heat-inactivated FCS
(Life Technologies) (R10) supplemented with 2.5% Cellkines
(Helvetica Healthcare, Geneva, Switzerland), 200 IU/ml IL-2
(PeproTech, Rocky Hill, NJ), and 25 ng/ml IL-15 (PeproTech).
Hmy.2 C1R B-cells expressing full-length HLA-A*0201 were
generated as described previously (41).
Protein Expression, Refolding, and Purification—The ILA1
TCR, HLA-A*0201 -chain, and human 2-microglobulin
chain sequences were generated as described previously (20)
and cloned into separate pGMT7 expression plasmids under
the control of the T7 promoter. The ILA1 TCR and HLA-
A*0201 in complex with various different peptide variants (as
indicated) were refolded and purified as described previously
(14). Biotinylated pMHCIwas prepared as described previously
(42).
pMHC Stability Assays—Thermal stability of the HLA-
A*0201-peptide complexes was assessed by circular dichroism
spectroscopy, monitoring the change in ellipticities at 218 nm
upon heating as described (31). Briefly, samples were prepared
in PBS at a concentration of 3 M and measured in 0.1-cm
quartz cells.Melting curveswere analyzed assuming a two-state
trimer-to-monomer transition from the native to unfolded
conformation and fitted as described (43). As all protein com-
plexes aggregated to various degrees upon unfolding, the ellip-
ticity of the unfolded state was set as a constant of 1.35 M1
cm1 (44).
Surface Plasmon Resonance Analysis—Binding analysis was
performed in duplicate using a BIAcoreT200TM equipped with
a CM5 sensor chip as described previously (45). Approximately
200–500 response units ofHLA-A*0201-ILGKFLHRLorHLA-
A*0201-ILAKFLHRL peptide complex was attached to the
CM5 sensor chip at a slow flow rate of 10 l/min to ensure
FIGURE 7.pEC50 values for all peptide ligands tested. Simultaneous curve fittingwas used to estimate functional sensitivitymeasured as pEC50 for peptides
sampled from the following sets: I, XLGXXXXRL (set size, 195; 30 peptides sampled at random); II, XLXKFLXXL (set size, 194; 30 peptides sampled at random); III,
XLG(K/L)F(L/I)(M/F/Y/N/H)(R/T/Y/K/S/F/H/I/L/M/Q/V/G/N)(L/V) (set size, 10,640; 30 peptides sampled at random); IV, (A/I/L/M/P/Q/W)L(G/A)(K/L)F(L/I)(N/H)(F/
K/N/Q/T/Y)(L/V); and V, replicate of a biased sampling of each set (20 peptides sampled from an effective sample size of 1.5 107).
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uniform distribution on the chip surface. HLA-A*0201-ILAK-
FLHWL was used as a positive control as the binding affinity
with the ILA1 TCR has been published previously (15, 20). The
ILA1 TCR was purified and concentrated to 300 M on the
same day of surface plasmon resonance analysis. For equilibrium
analysis, 10 serial dilutions were prepared in duplicate for each
sample and injected over the relevant sensor chips at 25 °C. TCR
was injected over the chip surface using kinetic injections at a flow
rate of 45l/min usingHLA-A*0201-ALWGPDPAAA as a nega-
tive control surface on flow cell 1. Results were analyzed using
BIAevaluationTM 3.1, Excel, andOrigin 6.0 software. The equilib-
riumdissociation constant (KD) valueswere calculated assuming a
1:1 interaction by plotting specific equilibrium binding responses
against protein concentrations followedbynon-linear least square
fitting of the Langmuir binding equation. For kinetics analysis, the
kon andkoff valueswerecalculatedassuming1:1Langmuirbinding,
and the data were analyzed using a global fit algorithm (BIAevalu-
ation 3.1).
Crystal Structure Determination—All protein crystals were
grown at 18 °C by vapor diffusion via the sitting drop technique.
200 nl of each pMHCI (10 mg/ml) in crystallization buffer (10
mM Tris, pH 8.1, and 10 mM NaCl) was added to 200 nl of
reservoir solution. ILA1-HLA-A*0201-ILAKFLHWL (ILA1-
A2-ILA) and HLA-A*0201-ILAKFLHTL (A2-ILA8T) crystals
were grown in 0.2M ammonium sulfate, 0.1 MHEPES, pH7, and
20% PEG 8000 (46); HLA-A*0201-ILGKFLHRL (A2-ILA3G8R)
crystals were grown in 0.2 M ammonium sulfate, 0.1 M Tris, pH
7.5, and 25% PEG 8000 (46); HLA-A*0201-ILGKFLHWL (A2-
ILA3G) crystals were grown in 0.2 M ammonium sulfate, 0.1 M
MES, pH 7, and 15% PEG 8000; andHLA-A*0201-ILAKFLHEL
(A2-ILA8E) crystals were grown in 0.2 M ammonium sulfate,
0.1 M MES, pH 7, and 25% PEG 8000 (46). Crystallization
screens were conducted using an Art-Robbins Phoenix dis-
pensing robot (Alpha Biotech Ltd., UK), and data were col-
lected at 100 K at the Diamond Light Source, Oxfordshire,
UK, at a wavelength of 0.98 Å using an Area Detector Sys-
tems Corp. Q315 charge-coupled device detector. Reflection
intensities were estimated using XIA2 (47), and the data
were analyzed with SCALA and the CCP4 package (48).
Structures were solved with molecular replacement using
Phaser (49). Sequences were adjusted with Coot (50), and the
models were refined with REFMAC5. Graphical representa-
tions were prepared with PyMOL (35). The reflection data
and final model coordinates were deposited with the Protein
Data Bank under codes 5MEN (ILA1-A2-ILA), 5MEO (A2-
ILA3G8R), 5MEP (A2-ILA3G), 5MEQ (A2-ILA8T), and
5MER (A2-ILA8E).
CD8 T-cell Effector Function Assays: MIP1 ELISA—6 
104 C1R-A2 cells were incubated with peptide at various con-
centrations in duplicate for 2 h at 37 °C. Subsequently, 3 104
ILA1 CD8 T-cells were added, and the assay was incubated
overnight at 37 °C. The supernatant was harvested and assayed
for MIP1 by ELISA according to the manufacturer’s instruc-
tions (R&D Systems). Functional sensitivity of individual pep-
tides was expressed as the pEC50 of each peptide, which is
defined as 1  the base 10 logarithm (p) of the 50% efficacy
concentration (EC50).
Quantification of ILA1 TCR Degeneracy—The degeneracy of
the ILA1 TCR was estimated as described previously (3).
Briefly, the degeneracy at 
, defined as the number of peptides
whose functional sensitivity is at least as large as 
, was esti-
mated directly using importance sampling based on the combi-
natorial peptide library scan and bounded below by sampling
from motif-based subsets of the peptide universe. The degen-
eracy is reported by plotting this quantity as a function of 

where the functional sensitivity
was scaled relative to a clone-
specific reference peptide (the “index”).
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FIGURE 8. TCR binding footprint contributes to T-cell cross-reactivity. A, peptide recognition degeneracy for ILA1. The degeneracy curve plots the
estimated number of peptides that have a functional sensitivity at least as strong as abscissa. The highest value of abscissa corresponds to inferred functional
sensitivity of optimal peptide, whereas the lowest value of abscissa lies 10 orders of magnitude below this optimum. Bias, degeneracy curve based on
agonist-biased importance sampling. Curves I–IV are motif-based, i.e. sampled from subsets of the entire peptide universe, and therefore lie below the
degeneracy curve. I, XLGXXXXRL (set size, 195; 30 peptides sampled at random); II, XLXKFLXXL (set size, 194; 30 peptides sampled at random); III, XLG(K/L)F(L/
I)(M/F/Y/N/H)(R/T/Y/K/S/F/H/I/L/M/Q/V/G/N)(L/V) (set size, 10,640; 30 peptides sampled at random); IV, (A/I/L/M/P/Q/W)L(G/A)(K/L)F(L/I)(N/H)(F/K/N/Q/T/
Y)(L/V) (set size, 1344; 19peptides sampledat random);Xdenotes anyof the19 aminoacids excluding cysteine. Cross-reactivity of the1E6 (B) and ILA1 (C) CD8
T-cell cloneswas estimatedby thenumberof residues recognized in a combinatorial peptide library screengenerating responsesover0.5ng/mlMIP-1.Bars
that representpositions in thepeptide that are anchor residues are coloredgray.Bars that represent residues that aremain contact sites for each respective TCR
are colored red.
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